Aeolus Pharmaceuticals

Development of new classes of disease modifying antioxidant small molecules, initially targeting neurodegenerative disorders.

Incara Pharmaceuticals Corporation changed its name to Aeolus Pharmaceuticals, Inc. effective July 16, 2004.
The record date for the company’s reverse split of stock was the close of business on July 15, 2004. Common stock began trading on a split-adjusted basis as of July 16, 2004 under the symbol AOLS.
The Group also developed adult liver stem cell therapy for the treatment of liver failure, which was sold in October 2002. On October 31, 2002, the Group sold substantially all the assets of its wholly owned subsidiary, Incara Cell Technologies, Inc. to Vesta Therapeutics. The scientific founders are James D. Crapo, Brian J. Day, and Irwin Fridovich, PhD.

Richard P. Burgoon, Jr., Esq., MBA, CEO
John L. McManus, President
Brian J. Day, Ph.D., CSO
Elaine Alexander, MD, Ph.D., VP, CMO
Michael McManus, Chief Accounting Officer

David C. Cavalier, Chairman
John M. Farah,Jr., PhD
Joseph J. Krivulka
Amit Kumar, PhD
Michael E. Lewis, PhD
Chris A. Rallis
Peter D. Suzdak, PhD

23811 Inverness Place
Laguna Niguel, California 92677
USA
Phone: +1-949-481-9825
Fax: +1-949-481-9829

Aeolus Pharmaceuticals is developing a series of catalytic antioxidant molecules which protect against the damaging effects of reactive oxygen derived molecules. Aeolus’ compounds have demonstrated efficacy in preclinical models of amyotrophic lateral sclerosis (ALS), cancer, stroke and chronic obstructive pulmonary disease. Examples include: AEOL 10113 inhibits the regrowth of tumors following radiation therapy in a mouse model of cancer. AEOL 10150 has been tested in an Amylotrophic Lateral Sclerosis (ALS) model in an initial and then a confirmatory experiment. Catalytic antioxidants AEOL 10113 and AEOL 10150 also significantly reduce damaged brain tissue.